Clinical Trials Logo

Clinical Trial Summary

This clinical trial is studying patient, physician, and nurse factors associated with entry onto clinical trials and finishing treatment in patients with primary or recurrent uterine, endometrial, or cervical cancer. Determining how patients make decisions about participating in a clinical trial may help doctors plan clinical trials in which more patients are willing to participate and are satisfied with their decision to participate.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine if there are specific, modifiable factors relative to patients, physicians, nurses, or clinical trial designs that predict enrollment or non-enrollment onto a GOG therapeutic trial for patients with primary or recurrent invasive cancer of the uterine corpus or cervix.

II. To determine if the Functional Comorbidity Index is an independent predictor of enrollment in a GOG clinical trial and if it correlates with performance status.

SECONDARY OBJECTIVES:

I. To determine, through multivariate analyses, whether the distribution of patients into a GOG clinical trial entry status categories (i.e., enrolled, not enrolled but eligible, not eligible) varies by demographics or economic status of patients, by patients' beliefs/concerns and interactions with physicians/family and friends, or by nurses' or physicians' beliefs/concerns and interactions with patients.

II. To determine whether patients' beliefs/concerns or interactions are associated with patient, nurse, or physician demographics.

III. To determine whether physicians' beliefs/concerns or interactions are associated with patient or physician demographics.

IV. To perform descriptive analysis regarding factors associated with completion of treatment through analysis of the Treatment Review Form.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups.

GROUP I (limited participation): Patients do not complete any questionnaires at baseline.

GROUP II (full participation): Patients complete the Patient Registration Survey and Patient Questionnaire at baseline.

At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration. ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Recurrent Cervical Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Recurrent Uterine Corpus Sarcoma
  • Sarcoma
  • Stage I Uterine Corpus Cancer
  • Stage I Uterine Sarcoma
  • Stage IA Cervical Cancer
  • Stage IB Cervical Cancer
  • Stage II Uterine Corpus Cancer
  • Stage II Uterine Sarcoma
  • Stage IIA Cervical Cancer
  • Stage IIB Cervical Cancer
  • Stage III Cervical Cancer
  • Stage III Uterine Corpus Cancer
  • Stage III Uterine Sarcoma
  • Stage IV Uterine Corpus Cancer
  • Stage IV Uterine Sarcoma
  • Stage IVA Cervical Cancer
  • Stage IVB Cervical Cancer
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms

NCT number NCT01098630
Study type Observational
Source Gynecologic Oncology Group
Contact
Status Completed
Phase
Start date July 2010
Completion date January 27, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Recruiting NCT04574635 - Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03439085 - DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Recruiting NCT05290935 - Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Phase 2
Recruiting NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer Phase 2
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2